Overview

This trial is active, not recruiting.

Condition peri-implantitis
Treatments gbo and gbg, standard treatment
Phase phase 4
Sponsor Geistlich Pharma AG
Start date September 2014
End date February 2017
Trial size 90 participants
Trial identifier NCT02375750, GS13530231

Summary

The primary objective of the study is to proof the successful use of Geistlich Bio-Oss® and Geistlich Bio-Gide® (already registered medical devices) in bony peri-implant defects due to peri-implantitis disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
0.2 g-0,5 g GBO and 1 GBG once after decontamination of implant surface
gbo and gbg
Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
(Active Comparator)
Decontamination of surface of implant
standard treatment
Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing

Primary Outcomes

Measure
Change in the dimensions of the bone defect
time frame: 6 months, 1 year

Secondary Outcomes

Measure
Change in pocket depth
time frame: 3 months,6months, 9 months,12months
Change in gingival inflammation
time frame: 3 months,6months, 9 months,12months
Changes in recession of the mucosal margin
time frame: 3 months,6months, 9 months,12months
Subject satisfaction with the outcome at the study end
time frame: 12months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - age 18 years or older - Presence of peri-implantitis - A peri-implant intraosseous defect with at least 3 mm defect depth as seen on an intraoral radiograph. - Clinically a probing depth ≥ 5 mm combined with bleeding and/or pus should be present at the site. - During surgical exploration an intraosseous component of at least 3 mm at the deepest point must be present. - The defect should have a minimum of 3 osseous walls (a circumference of the osseous defect of at least 270 degrees). Only 3 and 4 wall intraosseous defects will be included. - Implants included in the study must have been in function for more than 12 months. - Ability to fully understand the nature of the proposed surgery and ability to sign an Ethics Committee-approved informed consent form Exclusion Criteria: - Subjects with diabetes mellitus (HbA1c > 7.0) - Subjects taking prednisone or other anti-inflammatory prescription drug - Subjects taking medications known to have effects on gingival growth - If the same patient has more than one defect meeting the inclusion criteria, only one such defect will be included in the study - General contraindications for dental and/or surgical treatments - Smokers (> 10 cigarettes per day). - Pregnant or lactating women - Allergy to collagen - Inability to consent for participation in the study and/or to accept the proposed

Additional Information

Official title Surgical Treatment of Peri-implantitis Lesions, With or Without the Placement of a Bone Substitute and a Collagen Membrane. A Randomized Clinical Trial
Principal investigator Stefan Renvert, Professor
Description Patient who will considered eligible at the screening visit will undergo surgical treatment procedure within 2 weeks. At the day of the surgery the patients will be randomized into the 2 treatment groups. The subjects will be then prescribed postoperative antibiotics (Azitromax 500 mg day one and 250 mg day 2-4). Post-operative pain will be controlled with Ibuprofen (400mg x 3) for two days to all subjects. Subjects will rinse twice daily with Chlorhexidine mouth rinse and use modified oral hygiene procedures during the first 5 weeks of healing. Subjects will receive professional prophylaxis as required. Subjects will be instructed on appropriate oral hygiene throughout the study and will be given appropriate oral hygiene instructions. Instructions on post-operative care will be repeated at each visit. In particular the following points have to be covered during the first month after surgery: Chlorhexidine rinses, avoidance of brushing, usage of interdental cleaning devices, avoidance of chewing on or trauma to the treated area. In addition subjects will be instructed not to smoke more than 10 cigarettes per day during the entire study period and not to consume alcohol during antibiotic therapy. Sutures will be removed after 14 days. Photos will be taken during the whole study to document the healing process. Further follow up visits will be scheduled 6 weeks and 3,6,9,12 months post-surgery.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Geistlich Pharma AG.